Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Viswabandya, Auro  [Clear All Filters]
Journal Article
Nannya Y, Viswabandya A, Lu P. Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia. Blood Cell Ther. 2022;5(Spec Edition):S25-S33.
Nampoothiri RVasudevan, Pasic I, Law ADatt, Lam W, Chen C, Michelis FV, Kim DDong Hwan, Gerbitz A, Lipton JHoward, Kumar R, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy-Related Hematologic Malignancies Developing After Multiple Myeloma. Eur J Haematol. 2022.
Novitzky-Basso I, Remberger M, Chen C, Ellison C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, et al. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. Eur J Haematol. 2021.
Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, et al. ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2021.
Pereira MPinto, Remberger M, Chen C, Gerbitz A, Kim DDong Hwan, Kumar R, Lam W, Law ADatt, Lipton JH, Michelis FV, et al. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023.
Chendamarai E, Ganesan S, Alex AAbu, Kamath V, Nair SC, Nellickal AJose, Janet NBeryl, Srivastava V, Lakshmi KM, Viswabandya A, et al. Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. PLoS One. 2015;10(3):e0121912.
Moya TAlfaro, Salas MQueralt, Carreira ASantos, Atenafu EG, Law ADatt, Lam W, Pasic I, Kim DDong Hwan, Michelis FV, Basso INovitzky, et al. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies. Bone Marrow Transplant. 2024.
Alotaibi AS, Prem S, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, et al. Fresh versus Frozen Allogeneic Peripheral Blood Stem Cell Grafts: a Successful Timely Option. Am J Hematol. 2020.
Al-Shaibani E, Chen S, Chen C, Pasic I, Michelis FV, Lam W, Law A, Novitzky-Basso I, Gerbitz A, Kim DD, et al. Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience. Ann Hematol. 2023.
Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A, Sindhuvi E, Lakshmi KM, Srivastava A. Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. PLoS One. 2013;8(4):e61637.
Moya TAlfaro, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, et al. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. Eur J Haematol. 2023.
Salas MQueralt, Lam SChenc Wils, Pasic I, Gerbitz A, Michelis FV, Kim DDong Hwan, Al-Shaibani Z, Lipton JHoward, Mattsson J, Kumar R, et al. Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML. Biol Blood Marrow Transplant. 2020.
Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D, Humar A. Letermovir as Salvage Therapy for CMV Infection in Transplant Recipients. Transplantation. 2019.
Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D, Humar A. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. Transplantation. 2020;104(2):404-409.
Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, Kim DDong Hwan, Lipton JHoward, et al. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. Eur J Haematol. 2019.
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, et al. Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability. Biol Blood Marrow Transplant. 2019.
Nampoothiri RVasudevan, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, et al. Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis. Eur J Haematol. 2023.
Nampoothiri RVasudevan, Chen S, Pasic I, Al-Shaibani Z, Lam W, Michelis FV, Kim DDong Hwan, Viswabandya A, Gerbitz A, Lipton JHoward, et al. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2020.
Linn SMar, Nampoothiri RVasudevan, Chen C, Pasic I, Al-Shaibani Z, Lam W, Law ADatt, Michelis FV, Kim DDH, Gerbitz A, et al. Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematol Oncol Stem Cell Ther. 2021.
Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, et al. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Acta Haematol. 2020:1-8.
Novitzky-Basso I, Patriquin C, Linn SMar, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, et al. Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in third-line or beyond treatment for chronic GvHD. Transplant Cell Ther. 2023.
Salas MQueralt, Prem S, Atenafu EG, Law ADatt, Lam W, Al-Shaibani Z, Loach D, Kim DDong Hwan, Michelis FV, Lipton JHoward, et al. Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia. Eur J Haematol. 2019.
Salas MQueralt, Lam W, Law ADatt, Kim DDong Hwan, Michelis FV, Loach D, Al-Shaibani Z, Lipton JHoward, Kumar R, Mattsson J, et al. Reduced Intensity Conditioning Allogeneic Transplant with Dual T-cell Depletion in Myelofibrosis. Eur J Haematol. 2019.
Basso INovitzky, AlHayli S, Shin E, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, et al. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. Eur J Haematol. 2021.
Linn SM, Novitzky-Basso I, Abduljalil O, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, et al. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. Hematol Oncol Stem Cell Ther. 2023;17(1):60-71.

Pages